Journal: Molecular Cancer Research

Article Title: Norepinephrine Promotes the β1-Integrin–Mediated Adhesion of MDA-MB-231 Cells to Vascular Endothelium by the Induction of a GROα Release

doi: 10.1158/1541-7786.mcr-11-0130

Figure Lengend Snippet: Figure 6. Expression and function of the chemokine receptors CXCR1 and CXCR2 in tumor cell adhesion to HMVECs under flow conditions. A, the expression of the chemokine receptors CXCR1 and CXCR2 was investigated by PCR. b-Actin served as loading control. The standard is a 100-bp ladder. B, confirmatory experiments were carried out with PC-3 human prostate carcinoma cells. Left, adhesion of the cells to HMVECs under flow conditions; right, PCR of CXCR1 and CXCR2 expression. C and D, adhesion of MDA-MB-231 cells to HMVECs under flow conditions. C, the cells were pretreated with antibodies blocking the chemokine receptors (aCXCR1/2) or an isotypic control antibody (IgG2a). D, the endothelium was overlaid with GROa and IL-8 at a concentration of 1 mg/mL for 3 minutes before the experiment. Denaturated chemokines were used as control. Graphs in (C) and (D) show mean values and SDs of 3 independent experiments. , statistically significant changes (P < 0.05). Nor, norepinephrine.

Article Snippet: For blocking experiments, MDA-MB231 were preincubated for 10 minutes with monoclonal mouse anti-CXCR1 and anti-CXCR2 (each 5 mg/mL; R&D Systems), mouse IgG2a (10 mg/mL; R&D Systems), mouse anti-b1-integrin clone 4B4 (5 mg/mL; Beckman Coulter), or mouse IgG1 (5 mg/mL; Beckman Coulter).

Techniques: Expressing, Control, Blocking Assay, Concentration Assay

Journal: Molecular Cancer Research

Article Title: Norepinephrine Promotes the β1-Integrin–Mediated Adhesion of MDA-MB-231 Cells to Vascular Endothelium by the Induction of a GROα Release

doi: 10.1158/1541-7786.mcr-11-0130

Figure Lengend Snippet: Figure 7. Inhibition of b1-integrins and NF-kB abrogates the effect of norepinephrine on MDA-MB-231 cell adhesion. A, MDA-MB-231 cells were pretreated with either the b1-integrin–blocking antibody 4B4 or an isotypic control antibody (IgG1). B, HMVECs were preincubated with an NF-kB activation inhibitor (NF-kB Inh); norepinephrine (Nor) was used at 10 mmol/L. Both graphs show mean values and SDs of 3 independent experiments. , statistically significant changes (P < 0.05).

Article Snippet: For blocking experiments, MDA-MB231 were preincubated for 10 minutes with monoclonal mouse anti-CXCR1 and anti-CXCR2 (each 5 mg/mL; R&D Systems), mouse IgG2a (10 mg/mL; R&D Systems), mouse anti-b1-integrin clone 4B4 (5 mg/mL; Beckman Coulter), or mouse IgG1 (5 mg/mL; Beckman Coulter).

Techniques: Inhibition, Blocking Assay, Control, Activation Assay

Journal: bioRxiv

Article Title: Macrophages regulate meiotic initiation and germ cell clearance in the developing ovary

doi: 10.64898/2026.02.28.708733

Figure Lengend Snippet: (a) Representative whole-mount images of E13.5 ovaries from C57BL/6J embryos exposed at E6.5 to either control rat IgG2a antibody or anti-CSF1R blocking antibody to deplete YS-derived macrophages. For F4/80, PECAM1, and FOXL2 staining, n =5 control and n =6 anti-CSF1R-treated independent gonads; for CD11b and CD45 staining, n =3 control and n =3 anti-CSF1R-treated independent gonads. Insets show higher-magnification views of boxed regions; dashed lines mark the gonad-mesonephros boundary. (b) qRT-PCR analysis of macrophage-associated genes ( Adgre1, Cx3cr1, Csf1r, Mrc1 ) and endothelial marker Cdh5 , showing fold change in gene expression in E13.5 anti-CSF1R-treated ovaries versus controls. (c) Representative E14.5 sections stained for SYCP3 and TRA98 showing increased meiotic germ cells in anti-CSF1R-treated ovaries ( n =4) compared with control ovaries ( n =4). (d) qRT-PCR analysis of germ cell and meiotic genes ( Kit, Pou5f1, Ddx4, Stra8, Sycp1, Sycp3, Syce1, Smc1b ), showing fold change in gene expression in E14.5 anti-CSF1R-treated ovaries versus controls. (e) Representative E18.5 sections stained for F4/80 and CD45, and for SYCP3 and FOXL2, showing recovery of F4/80⁺ macrophages and advanced meiotic progression in anti-CSF1R-treated ovaries compared with control ovaries. For F4/80 and CD45 staining, n =4 control and n =4 anti-CSF1R-treated independent gonads; for SYCP3 and FOXL2 staining, n =3 control and n =3 anti-CSF1R-treated independent gonads. Arrows indicate SYCP3⁺ dictyate-stage oocytes. (f) Percentage of SYCP3⁺ germ cells at the dictyate stage among total SYCP3⁺ cells at E18.5. Data are shown as mean +/− SD. * P <0.05, ** P <0.01, *** P <0.001 (two-tailed Student’s t -tests). Scale bars, 100 μm (overview) and 50 μm (higher magnification/insets).

Article Snippet: To transiently deplete yolk-sac-derived and fetal CSF1R + macrophages, pregnant C57BL/6J females were injected intraperitoneally with 3 mg anti-CSF1R monoclonal antibody (mAb; clone AFS98, Bio X Cell #BP0213) or rat IgG2a isotype control (Bio X Cell #BP0089).

Techniques: Control, Blocking Assay, Derivative Assay, Staining, Quantitative RT-PCR, Marker, Gene Expression, Two Tailed Test

Journal: bioRxiv

Article Title: Macrophages regulate meiotic initiation and germ cell clearance in the developing ovary

doi: 10.64898/2026.02.28.708733

Figure Lengend Snippet: (a) Representative images of E18.5, P3, and P10 ovaries from C57BL/6J embryos exposed at E6.5 and E14.5 to either control rat IgG2a antibody or anti-CSF1R blocking antibody to deplete fetal ovarian macrophages. For E18.5, n =4 control and n =4 anti-CSF1R-treated independent gonads; for P3, n =6 control and n =6 anti-CSF1R-treated independent gonads; for P10, n =4 control and n =4 anti-CSF1R-treated independent gonads. Insets show higher-magnification views of boxed regions; red and green dashed outlines demarcate the ovary. (b) Representative sections stained for DDX4, showing developmental germ cell attrition at E18.5, P3, and P10 in control and anti-CSF1R-treated ovaries. For each time point, n =4 control and n =4 anti-CSF1R-treated independent gonads. (c) Quantification of CD45⁺IBA1 + macrophages per 0.1 mm² ovarian area at E18.5, P3, and P10. (d) Quantification of CD45⁺IBA1 − monocyte-like cells per 0.1 mm² ovarian area at the indicated stages. (e) Quantification of DDX4⁺ germ cell number per 0.1 mm² ovarian area at E18.5, P3, and P10, showing reduced physiological germ cell loss after macrophage depletion. Data are shown as mean +/− SD. * P <0.05, ** P <0.01, *** P <0.001 (two-tailed Student’s t -tests). Scale bars, 100 μm (overview) and 50 μm (higher magnification/insets).

Article Snippet: To transiently deplete yolk-sac-derived and fetal CSF1R + macrophages, pregnant C57BL/6J females were injected intraperitoneally with 3 mg anti-CSF1R monoclonal antibody (mAb; clone AFS98, Bio X Cell #BP0213) or rat IgG2a isotype control (Bio X Cell #BP0089).

Techniques: Control, Blocking Assay, Staining, Two Tailed Test

Journal: Journal of Veterinary Science

Article Title: Efficacy of strain RB51 vaccine in protecting infection and vertical transmission against Brucella abortus in Sprague-Dawley rats

doi: 10.4142/jvs.2009.10.3.211

Figure Lengend Snippet: Total serum IgG, IgG1 and IgG2a levels of non-vaccinated control and RB51-vaccinated rats 3 weeks after challenge with B. abortus biotype 1 (A) and at necropsy (B). Antibody titers are reported as mean ± SE. Statistically significant difference among RB51-vaccinated, non-vaccinated pregnant and non-pregnant control rats are indicated by asterisks ( * p < 0.05 and † p < 0.001).

Article Snippet: Affinity purified rat IgG, IgG1 and IgG2a (Bethyl Laboratories, USA) were used to coat the 96-well plate starting from 500 ng/well to 7.8 ng/well to generate the standard curve.

Techniques: Control

Journal: Journal of the American Society of Nephrology

Article Title: Nasal Administration of Recombinant Rat α3(IV)NC1 Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat

doi: 10.1681/asn.2004121026

Figure Lengend Snippet: Figure 3. Effect of nasal administration of recombinant 3(IV)NC1 on circulating levels of IgG1 (A) and IgG2a (B) anti-3(IV)NC1 antibodies in groups of WKY rats (n 5 to 8) with EAG. Results shown represent the mean SD of each group at week 4 after immunization. *P 0.05, positive control versus 3(IV)NC1 250 g nasally.

Article Snippet: The isotypes of circulating anti- 3 antibodies were detected by mouse mAb specific for rat IgG1 and IgG2a (Serotec Ltd, Oxford, UK), followed by goat anti-mouse IgG (Serotec Ltd).

Techniques: Recombinant, Positive Control

Journal: Journal of the American Society of Nephrology

Article Title: Nasal Administration of Recombinant Rat α3(IV)NC1 Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat

doi: 10.1681/asn.2004121026

Figure Lengend Snippet: Figure 6. Effect of nasal administration of recombinant 3(IV)NC1 on deposits of IgG on the glomerular basement membrane (GBM) in groups of WKY rats (n 5 to 8) with EAG. Results shown represent the mean SD of each group at week 4 after immunization. *P 0.01, positive control versus 3(IV)NC1 100 g nasally; **P 0.001, positive control versus 3(IV)NC1 250 g nasally.

Article Snippet: The isotypes of circulating anti- 3 antibodies were detected by mouse mAb specific for rat IgG1 and IgG2a (Serotec Ltd, Oxford, UK), followed by goat anti-mouse IgG (Serotec Ltd).

Techniques: Recombinant, Membrane, Positive Control

Journal: Journal of the American Society of Nephrology

Article Title: Nasal Administration of Recombinant Rat α3(IV)NC1 Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat

doi: 10.1681/asn.2004121026

Figure Lengend Snippet: Figure 7. Direct immunofluorescence of kidney tissue at week 4 from WKY rats with EAG showing strong linear deposits of IgG on the GBM in a positive control animal (A) and marked reduction in the deposition of IgG on the GBM (B) in an animal that was given recombinant 3(IV)NC1 250 g nasally. Magni- fication, 300.

Article Snippet: The isotypes of circulating anti- 3 antibodies were detected by mouse mAb specific for rat IgG1 and IgG2a (Serotec Ltd, Oxford, UK), followed by goat anti-mouse IgG (Serotec Ltd).

Techniques: Immunofluorescence, Positive Control, Recombinant